Transforming Manufacturing Through Integrated Flow Technologies at Asymchem
Leading the Shift to Greener Processes
Pharmaceutical manufacturing is entering a new era of transformation. Globally, regulatory expectations are rising and the demand for safer, cleaner and more efficient manufacturing practices is becoming increasingly urgent. Sustainability is no longer optional; it is now a driving force that is pushing the industry to rethink long-established approaches. Flow chemistry is emerging as a key solution, but its full impact depends on more than just technology. Meaningful progress happens when process expertise, equipment design and engineering integration come together. At Asymchem, they bring these capabilities under one roof. With deep expertise and a proven track record in flow chemistry, they help clients improve efficiency, reduce environmental impact and scale the production of RSMs, intermediates and APIs with confidence.
Scope and Capabilities
Asymchem was among the first CDMOs to implement continuous manufacturing for pharmaceuticals and fine chemicals, beginning in 2008. Since then, they have delivered more than 500 flow projects over kilo-scale and enabled technology transfer projects at scales up to 10,000 MT. With nearly two decades of experience and fully integrated capabilities, Asymchem is equipped to address some of the most complex challenges in pharmaceutical manufacturing. They have established capabilities to perform virtually all reactions in flow mode, encompassing liquid-liquid, gas–liquid, solid-liquid, gas-liquid-solid and other multiphase reactions, with demonstrated excellence in hydrogenation, nitration and lithiation, etc. These technologies enable the precise, scalable and efficient production of pharmaceutical intermediates and APIs.
At Asymchem, innovation is core to how they solve complex manufacturing challenges. To address the difficulties of continuous solid-liquid reactions, they developed and built their own proprietary flow reactor, using etformin synthesis as the test platform throughout its design and optimisation. This breakthrough led to multiple patents for continuous metformin production and resulted in China’s first API continuous manufacturing verification under the ICH Q13 guidelines. By leading this effort, Asymchem is helping to drive broader adoption of continuous manufacturing across the industry.
